0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > LIV-1

LIV-1

Brief Information

Name:Zinc transporter ZIP6
Target Synonym:LIV-1,LIV1,LIV-1 Protein, Estrogen Regulated,Solute Carrier Family 39 (Metal Ion Transporter), Member 6,Zrt- and Irt-like protein 6,SLC39A6,Estrogen-regulated protein LIV-1,ZIP-6,Zinc transporter ZIP6,Solute Carrier Family 39 (Zinc Transporter), Member 6,Solute carrier family 39 member 6
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
LIV-1 mAb - 01 PCC Solid Tumor Colorectal cancer,Breast cancer

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

LV1-H5223-SPR
 LIV-1 SPR

Anti-LIV-1 mAb captured on CM5 chip via anti-human IgG Fc antibody can bind Human LIV-1, His Tag (Cat. No. LV1-H5223) with an affinity constant of 5.24 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

LV1-H5254-SPR
 LIV-1 SPR

Anti-LIV-1 mAb immobilized on CM5 can bind Human LIV-1, Fc Tag (Cat. No. LV1-H5254) with an affinity constant of 1.74 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

SLC39A6,LIV-1,ZIP6,Zinc transporter ZIP6,ZIP-6

Background

LIV-1 is also known as SLC39A6, ZIP-6 and Zinc transporter ZIP6. May act as a zinc-influx transporter. Highly expressed in the breast, prostate, placenta, kidney, pituitary and corpus callosum. Weakly expressed in heart and intestine. Also highly expressed in cells derived from an adenocarcinoma of the cervix and lung carcinoma. Up-regulated by estrogen in breast cancer cells lines.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ladiratuzumab vedotin SGN-LIV1A; MK-6440; MK6440 Phase 2 Clinical Merck Sharp & Dohme Corp Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
BRY-812 BRY-812 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
Ladiratuzumab vedotin SGN-LIV1A; MK-6440; MK6440 Phase 2 Clinical Merck Sharp & Dohme Corp Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
BRY-812 BRY-812 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message